Profile data is unavailable for this security.
About the company
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
- Revenue in USD (TTM)0.00
- Net income in USD-39.95m
- Incorporated2004
- Employees34.00
- LocationAnavex Life Sciences Corp630 5Th Avenue, 20Th FloorNEW YORK 10111United StatesUSA
- Phone+1 (800) 689-3939
- Websitehttps://www.anavex.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Protara Therapeutics Inc | 0.00 | -52.90m | 334.57m | 28.00 | -- | 1.89 | -- | -- | -1.43 | -1.43 | 0.00 | 3.43 | 0.00 | -- | -- | 0.00 | -44.32 | -35.06 | -48.05 | -36.43 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.33 | -- | 31.54 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 342.80m | 123.00 | -- | 43.28 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| OpGen Inc | 9.00m | 6.70m | 345.08m | 1.00 | 51.63 | 33.71 | 50.08 | 38.34 | 0.6585 | 0.6585 | 0.8894 | 1.01 | 0.994 | -- | 4.42 | 9,000,000.00 | 75.58 | -74.71 | 81.77 | -111.02 | 100.00 | 30.79 | 76.04 | -602.64 | -- | -- | 0.00 | -- | 52.01 | 8.23 | 134.76 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -147.03m | 348.45m | 56.00 | -- | 1.10 | -- | -- | -1.78 | -1.78 | 0.00 | 4.04 | 0.00 | -- | -- | 0.00 | -35.26 | -9.87 | -37.29 | -11.45 | -- | -- | -- | -77.50 | -- | -- | 0.00 | -- | -- | -- | -23.85 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -240.91m | 350.64m | 299.00 | -- | 1.12 | -- | -- | -2.25 | -2.25 | 0.00 | 2.90 | 0.00 | -- | -- | 0.00 | -63.25 | -38.97 | -69.77 | -41.67 | -- | -- | -- | -- | -- | -- | 0.0635 | -- | -- | -- | -5.35 | -- | -24.10 | -- |
| Immix Biopharma Inc | 0.00 | -23.56m | 356.73m | 18.00 | -- | 27.34 | -- | -- | -0.7742 | -0.7742 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -104.21 | -108.46 | -169.47 | -146.18 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.11 | -- | 176.33 | -- |
| Aura Biosciences Inc | 0.00 | -106.47m | 356.89m | 106.00 | -- | 2.26 | -- | -- | -1.93 | -1.93 | 0.00 | 2.49 | 0.00 | -- | -- | 0.00 | -53.86 | -36.26 | -58.85 | -38.42 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -13.76 | -- | -10.82 | -- |
| Anavex Life Sciences Corp | 0.00 | -39.95m | 359.57m | 34.00 | -- | 2.84 | -- | -- | -0.4649 | -0.4649 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -31.08 | -33.08 | -33.63 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
| Aclaris Therapeutics Inc | 15.74m | -141.68m | 367.29m | 64.00 | -- | 3.06 | -- | 23.33 | -1.38 | -1.38 | 0.136 | 1.11 | 0.088 | -- | 6.27 | 245,968.80 | -79.17 | -48.16 | -90.39 | -55.11 | 3.98 | 40.68 | -900.01 | -483.49 | -- | -- | 0.00 | -- | -40.09 | 34.67 | -49.26 | -- | 86.02 | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 370.80m | 226.00 | -- | 1.17 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Forte Biosciences Inc | 0.00 | -51.74m | 373.93m | 16.00 | -- | 4.45 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Climb Bio Inc | 0.00 | -50.75m | 379.11m | 17.00 | -- | 2.14 | -- | -- | -0.7507 | -0.7507 | 0.00 | 2.60 | 0.00 | -- | -- | 0.00 | -25.09 | -39.53 | -25.62 | -41.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -110.42 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 384.19m | 4.00 | -- | 175.07 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 384.30m | 305.00 | -- | 0.6208 | -- | 13.56 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 390.84m | 32.00 | -- | 1.51 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
| Absci Corp | 2.82m | -114.60m | 390.97m | 156.00 | -- | 1.85 | -- | 138.89 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
Data as of Feb 11 2026. Currency figures normalised to Anavex Life Sciences Corp's reporting currency: US Dollar USD
23.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2025 | 6.33m | 7.09% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 4.33m | 4.85% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 3.29m | 3.68% |
| Geode Capital Management LLCas of 30 Sep 2025 | 2.03m | 2.27% |
| Two Sigma Investments LPas of 30 Sep 2025 | 1.04m | 1.16% |
| NWAM LLCas of 31 Dec 2025 | 870.80k | 0.98% |
| Two Sigma Advisers LPas of 30 Sep 2025 | 758.50k | 0.85% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 728.67k | 0.82% |
| Charles Schwab Investment Management, Inc.as of 30 Sep 2025 | 717.38k | 0.80% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 603.82k | 0.68% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
